Synthesis, resolution and applications of 3,3'-disubstituted BIPHEP and BINAP derivatives in asymmetric organic synthesis

3,3-二取代BIPHEP和BINAP衍生物的合成、拆分及其在不对称有机合成中的应用

基本信息

批准号：
335648-2005
负责人：
Keay, Brian
金额：
$ 1.09万
依托单位：
University of Calgary
依托单位国家：
加拿大
项目类别：
Collaborative Research and Development Grants
财政年份：
2008
资助国家：
加拿大
起止时间：
2008-01-01 至 2009-12-31
项目状态：
已结题

来源：
https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=398965
关键词：
Synthesis resolution applications disubstituted BIPHEP

项目摘要

The goal of this proposal is to develop new asymmetric catalysts and reagents that will provide products of reactions with high enantioselectivity. Compounds that are marketed as drugs that contain one or more stereogenic centres can exist as two enantiomers. It is important that chemists design new asymmetric catalysts that allows for the production of one enantiomer selectively over the other as each enantiomer can behave differently within a chiral environment like the human body. Thus in order to market a new drug containing stereogenic centres, each anantiomer must be synthesized independent of the other and tested separately for unwanted side effects. This is not an easy task as enantiomers have the same chemical and physical properties in a non-chiral environment (i.e in the laboratory where they are synthesized). Thus chemists must design new asymmetric catalysts that allow for the formation of one enantiomer over the other in the laboratory. The design of catalysts outlined in this proposal should allow for the production of enantiomers selectively. By having to avoid a resolution, the cost of making the drug should be lower and thus ultimately the consumer should pay less for their prescriptions. Thus this research could ultimately benefit anyone needing drugs that contain stereogenic centres.

该提案的目的是开发新的不对称催化剂和试剂，这些催化剂和试剂将提供具有高对映选择性的反应产物。作为包含一个或多个立体中心的药物销售的化合物可以作为两个对映异构体存在。重要的是，重要的是，化学家设计新的不对称催化剂，可以选择性地生产一个对映异构体，因为每个对映体在人体（如人体）中的表现可能会有所不同。因此，为了销售含有立体源性中心的新药物，必须独立于另一个疾病来合成每种厌食症，并分别测试是否有不需要的副作用。这不是一件容易的事，因为对映异构体在非手续环境中具有相同的化学和物理特性（即在合成的实验室中）。因此，化学家必须设计新的不对称催化剂，以使一个对映异构体在实验室中形成。该提案中概述的催化剂的设计应允许选择性地生产对映异构体。通过避免解决方案，制造药物的成本应降低，因此最终消费者应为他们的处方支付更少的费用。因此，这项研究最终可以使需要有立体中心的药物的任何人受益。